AURKA and neuroblastoma: Emerging pre-clinical evidence suggests that inhibitors targeting AURKA, such as MLN8237 (Görgün et al., 2010) and ENMD-2076 (Diamond et al., 2011), could disrupt NB progression and are currently undergoing clinical evaluation.